SHMT1 (Serine Hydroxymethyltransferase 1)

We conclude that reduced thymidylate synthesis causes folic acid-responsive NTDs and PN in mice and that diabetes sensitizes mice to folic acid-responsive PN. Diabetes induces a special nutritional requirement for high intake of folic acid to prevent PN.

Biomarkers such as xCT/GPX4 expression, PHGDH levels, Nrf2 activity, and GSH/NADPH ratios may guide patient stratification and response prediction. Overall, understanding the redox-amino acid metabolic network provides a mechanistic basis and translational opportunities for precision metabolic therapies in ovarian cancer.

Analysis of γH2AX demonstrates a prolonged duration of foci formation in cells after proton irradiation in the presence of BSH11. Further research will be needed to better understand the potential clinical applications of proton-boron interaction.

This study presents a validated prognostic risk score model comprising AAMRGs in LSCC. Furthermore, our findings highlight the downregulation of SHMT1 in LSCC and its significant association with patient prognosis and tumor stage.

Considering expression frequency, specificity, and functional relevance, FTCD, GPD1, SOD2, and EIF4B Ser422 phosphorylation are further identified and validated as subtype prognostic biomarkers. This study provides critical insights into the molecular mechanisms underlying CRLM and offers resources for high-risk metastatic CRC.

Our results revealed significant associations between amino acid metabolism gene polymorphisms and PTC risk, suggesting potential biomarkers for PTC susceptibility.

Furthermore, we obtained an X-ray structure of TthSHMT in complex with the substrate THF, which binds identically as 5MTHF at the peripheral binding site. The unique structural and functional information provided by neutron crystallography, in combination with X-ray structures, can be employed in the rational design of SHMT inhibitors.

While current evidence is predominantly preclinical, sertraline's multi-targeted action and established safety profile support its candidacy for repurposing. Further translational research and biomarker-driven clinical trials are warranted to validate its therapeutic niche and optimize its integration into oncology.

Folate transporter-null HeLa cells were engineered to express RFC under the control of a tetracycline-inducible promoter...The results document the therapeutic promise of classical multitargeted pyrrolo[3,2-d]pyrimidine antifolates typified by AGF347. These novel compounds offer an exciting new platform for one-carbon-targeted drug development for cancer.

In this review, we aimed to highlight the therapeutic potential of targeting SHMT and offer insights into the development of innovative treatment strategies in oncology and metabolic medicine. These insights support the hypothesis that targeting SHMT, particularly isoform-specific inhibition, may provide novel therapeutic avenues in both oncology and metabolic medicine.

Therefore, the research on abnormal expression of SHMT in tumor cells has profound significance for the diagnosis and treatment of cancer. This article reviews the structure, biological process, markers, and related drug treatment of SHMT protein, providing new ideas for the diagnosis and treatment of tumors.